Vanda Pharmaceuticals | VNDA - Trade Debtors


Vanda Pharmaceuticals reported $47.1M in Trade Debtors for its fiscal quarter ending in December of 2024.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 15.68M 203.19M Mar/2026
AstraZeneca USD 17.88B 1.17B Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Eli Lilly USD 21.18B 1.02B Mar/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Halozyme Therapeutics USD 457.99M 16.72M Mar/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Insmed USD 178.55M 37.7M Mar/2026
J&J USD 22.54B 1.21B Mar/2026
Lexicon Pharmaceuticals USD 2.38M 50K Dec/2025
Ligand Pharmaceuticals USD 54.8M 6.25M Mar/2026
Merck USD 11.78B 345M Dec/2025
Moderna USD 71M 113M Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 16.17B 332M Mar/2026
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 482M 85M Mar/2026
Takeda JPY 876.35B 118.43B Mar/2026
Teva Pharmaceutical Industries USD 3.39B 316M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Veracyte USD 50.11M 5.45M Mar/2026